A Phase 2 interventional study of Pimasertib and Pimasertib in Leukemia, Myeloid, Acute and Hematologic Neoplasms, sponsored by EMD Serono. Terminated at 9 sites in 2 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2017-08-21.
Sponsored by EMD Serono (part of Merck KGaA, Darmstadt, Germany) · Phase 2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 2,137 studies in Leukemia, Myeloid, Acute with a site in United States — 312 open to participants now, 466 under way, 24 of them phase 3. Leukemia, Myeloid, Acute · United States.
Among the 2,137 studies in Leukemia, Myeloid, Acute with a site in United States, this one is the 403rd largest by enrollment of the 1,907 interventional ones that give a count, is one of 75 that started in 2009, is one of 647 in phase 2, and was the 667th registered.
3,669 studies on the registry are indexed under Leukemia, Myeloid, Acute; 817 are open to participants now.
Browse Leukemia, Myeloid, Acute studies →312 of the 2,137 studies in Leukemia, Myeloid, Acute with a site in United States are open now. Recruiting first, the newest first:
Uma Borate · Sites in United States
Ages 18+
University of Washington · Sites in United States
Ages 18+
Fred Hutchinson Cancer Center · Sites in United States
Ages 18+
Washington University School of Medicine · Sites in United States
Ages 18+
City of Hope Medical Center · Sites in United States
Ages 18+
A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →
Of the 625 Leukemia, Myeloid, Acute studies recruiting now, 363 (58%) set no upper age limit and 222 (36%) stop at 75 or younger; 145 take children under 18; 29 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
2,137 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 1,078 · Phase 2 970 · Phase 3 139 · Phase 4 7
First in 1986; this study’s year is marked. 75 started in 2009.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 81 is above the median of 40 across 3,007 interventional studies indexed under Leukemia, Myeloid, Acute.
Median enrollment 35 across the 1,907 interventional studies, 98 across the 126 observational. Of the 1,556 that completed or were terminated, 708 (46%) have results posted.
This tab as a report to print or save as PDF → With an account.
574 of 2,137 have an industry lead sponsor. The 10 most frequent:
This study is registered under EMD Serono, one of the names counted as Merck KGaA, Darmstadt, Germany. Under that name alone:
EMD Serono is the lead sponsor of 91 studies on the registry; none are open to participants now.
Merck KGaA, Darmstadt, Germany has 1 study filed under Leukemia, Myeloid, Acute — fewer than ten, so there is no comparison to draw.
170 of the studies in Leukemia, Myeloid, Acute with a site in United States that are under way reach primary completion within a year, 4 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT05183035Phase 3PedAL BCU, LLCVenetoclax in Children With Relapsed Acute Myeloid Leukemia (AML) | 2027-02 |
| NCT05429632Phase 3Priothera SASMocravimod as Adjunctive and Maintenance Treatment in AML Patients Undergoing Allo-HCT | 2027-05 |
| NCT03844048Phase 3AbbVieAn Extension Study of Venetoclax for Subjects Who Have Completed a Prior Venetoclax Clinical Trial | 2027-08 |
| NCT04256317Phase 3Taiho Oncology, Inc.A Multi-phase Study of ASTX030 (Azacitidine and Cedazuridine) in Myeloid Neoplasm Alone or in Combination With Venetoclax in AML (AZTOUND Study) | 2027-11-01 |
| NCT03121014University of Illinois at ChicagoStudy of Intensity Modulated Total Marrow Irradiation (IM-TMI) in Addition to Fludarabine/Busulfan Conditioning for Allogeneic Transplantation in High Risk AML and Myelodysplastic Syndromes | 2026-11 |
Add all 170 to your calendar (.ics) → With an account.
Among the 2,137 studies in Leukemia, Myeloid, Acute with a site in United States, from their registry updates:
This tab as a report to print or save as PDF → With an account.
This is an open-label, multi-center, dose-escalation trial of pimasertib (MSC1936369B) in blood and bone marrow cancers. The trial will be conducted in two parts:
Part 1 (safety run-in period): Will determine the maximum tolerated dose (MTD) of the study drug in subjects with advanced hematological malignancies.
Part 2: Will assess the anti-leukemic activity of the study drug in older subjects with newly diagnosed poor prognosis acute myeloid leukemia (AML) who are not candidates for intensive chemotherapy.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Part 1:
Subjects with one of the following conditions:
Primary or secondary AML, confirmed according to World Health Organization (WHO) classification who meet at least one of the following conditions:
Part 2:
Subjects (male and female) with newly diagnosed primary or secondary AML pathologically confirmed according to WHO classification who have not been exposed to any prior therapy for AML with the exception of:
Subjects meet at least one of the following conditions:
Age greater than or equal to 60 and less than 75 years with at least one of the following poor prognostic factors:
Exclusion Criteria:
Part 1 and Part 2:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).
Your pathology report is the document that shows this.
Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.
Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.
Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.
Blood tests of how long blood takes to clot. The INR is the prothrombin time (PT) put on a common scale; about 1 is usual for someone not taking a blood thinner.
Criteria often make an exception for people on a blood thinner such as warfarin, whose INR is raised on purpose.
Histologically or cytologically confirmed
The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).
Your pathology report is the document that shows this.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Relapsed and refractory
Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Biopsy and archival tissue
A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.
Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ECOG performance status
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HIV
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis B tests
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis C tests
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Bilirubin
A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.
Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ULN (upper limit of normal)
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ALT and AST (liver enzymes)
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Creatinine clearance (CrCl)
How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
INR, PT and aPTT (clotting tests)
Blood tests of how long blood takes to clot. The INR is the prothrombin time (PT) put on a common scale; about 1 is usual for someone not taking a blood thinner.
Criteria often make an exception for people on a blood thinner such as warfarin, whose INR is raised on purpose.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Drug: Pimasertib
Drug: Pimasertib
Drug: Pimasertib
Drug: Pimasertib
Drug: Pimasertib
Pimasertib will be administered orally at a dose of 8 mg twice daily (BID) on Days 1 to 5, 8 to 12, 15 to 19, and 22 to 26 of a 28-day cycle. The dose will be escalated to 15 mg BID, 23 mg BID, 30 mg BID, 42 mg BID, 60 mg BID, and 75 mg BID) until Maximum Tolerated Dose (MTD) is reached. The treatment will be continued until disease progression, intolerable toxicity, or Investigator/subject decision.
Also known as: MSC1936369B
Pimasertib will be administered orally at a dose of 8 mg BID on Days 1 to 21 of a 28-day cycle. The dose will be escalated to 15 mg BID, 23 mg BID, 30 mg BID, 42 mg BID, 45 mg BID, 60 mg BID, 75 mg BID, and 90 mg BID until MTD is reached. The treatment will be continued until disease progression, intolerable toxicity, or Investigator/subject decision.
Also known as: MSC1936369B
Pimasertib will be administered orally at a dose of 60 mg BID on Days 1-28 of a 28-day cycle. The dose escalation will proceed to 75 mg BID until MTD is reached. The treatment will be continued until disease progression, intolerable toxicity, or Investigator/subject decision.
Also known as: MSC1936369B
Pimasertib will be administered orally twice daily on Days 1 to 5, 8 to 12, 15 to 19, and 22 to 26 of a 28-day cycle. Dose will be determined by Part 1 of the trial (could be the MTD or lower dose level). The treatment will be continued until disease progression, intolerable toxicity, or Investigator/subject decision.
Also known as: MSC1936369B
Pimasertib will be administered orally twice daily on Days 1 to 21 of a 28-day cycle. Dose will be determined by Part 1 of the trial (could be the MTD or lower dose level). The treatment will be continued until disease progression, intolerable toxicity, or Investigator/subject decision.
Also known as: MSC1936369B
Part 1: Number of Subjects With Dose Limiting Toxicities (DLTs)
The DLT was any toxicity that resulted in treatment delay for more than (\>) 2 weeks due to treatment-related adverse effects, or any Grade greater than or equal to (\>=) 3 non-hematological toxicity excluding Grade 4 asymptomatic increases in liver function tests reversible within 7 days in subjects with liver involvement, and Grade 3 asymptomatic increases in liver function tests reversible within 7 days for subjects without liver involvement, Grade 3 vomiting unless encountered and persistent for more than 3 days despite adequate and optimal therapy, and Grade 3 diarrhea unless encountered and persistent for more than 3 days despite adequate and optimal anti-diarrhea therapy at any DL and judged to be possibly or probably related to the trial treatment by the Investigator and/or the Sponsor.
Time frame: Baseline Up to Day 29 of Cycle 1
Part 2: Percentage of Subjects With Best Overall Response
The best overall response was to be reported as either of the following: (1) Morphologic complete remission (CR) = normalization of the peripheral blood absolute neutrophil count (PBANC) \>1.0x10\^9 per liter (/L), platelets \>100x10\^9 /L, bone marrow aspirate with less than or equal to (\<=) 5 percent (%) blasts, no blasts with Auer rods (AML only). (2) Complete remission with incomplete blood count recovery (CRi) = Same as CR without normalization of PBANC and platelet count. (3) Partial remission (PR) = normalization of PBANC \>1.0x10\^9/L, platelets \>100x10\^9/L, and at least a 50% decrease in the percentage of marrow aspirate blasts to 5-25%, or marrow blasts less than (\<) 5%. (4) Progressive disease (PD) = \>50% increase in peripheral blood or bone marrow blasts. (5) Stable disease (SD) = subjects who failed to achieve CR, CRi or PR and without criteria for PD.
Time frame: Day 29 of every 29-day cycle until progression reported between day of first subject randomized, September 2009, until cut-off date, December 2012
Part 1: Number of Subjects With Treatment-emergent Adverse Events (TEAEs), Serious TEAEs, TEAEs Leading to Death and TEAEs Leading to Permanent Treatment Discontinuation
An adverse event (AE) was defined as any new untoward medical occurrences/worsening of pre-existing medical condition, whether or not related to study drug. A serious adverse event (SAE) was an AE that resulted in any of the following outcomes: death; life threatening; persistent/significant disability/incapacity; initial or prolonged inpatient hospitalization; congenital anomaly/birth defect. TEAEs include both SAEs and non-SAEs.
Time frame: Baseline up to 3 years
Part 1: Maximum Plasma Concentration (Cmax) of Pimasertib Single Dose
Time frame: Predose 0.5, 1.0, 1.5, 2.0, 2.5, 4.0, 6.0, and 10.0 hours post-dose on Day 1 of cycle 1; Regimen 1, 2 and 3
Part 1: Maximum Plasma Concentration (Cmax) of Pimasertib Multiple Dose
Time frame: Pre dose 0.5, 1.0, 1.5, 2.0, 2.5, 4.0, 6.0, and 10.0 hours post dose in Cycle 1 on Day 19 to Day 21 (Regimen 1 and 2) or Day 26 (Regimen 3).
Part 1: Time to Reach Maximum Plasma Concentration (Tmax): Single Dose
Time frame: Predose 0.5, 1.0, 1.5, 2.0, 2.5, 4.0, 6.0, and 10.0 hours post-dose on Day 1 of cycle 1; Regimen 1, 2 and 3
Part 1: Time to Reach Maximum Plasma Concentration (Tmax): Multiple Dose
Time frame: Pre dose 0.5, 1.0, 1.5, 2.0, 2.5, 4.0, 6.0, and 10.0 hours post dose in Cycle 1 on Day 19 to Day 21 (Regimen 1 and 2) or Day 26 (Regimen 3)
Part 1: Apparent Terminal Half-Life (t1/2) of Pimasertib: Single Dose
The apparent terminal half-life was defined as the time required for the plasma concentration of drug to decrease 50% in the final stage of its elimination.
Time frame: Predose 0.5, 1.0, 1.5, 2.0, 2.5, 4.0, 6.0, and 10.0 hours post-dose on Day 1 of cycle 1; Regimen 1, 2 and 3
Part 1: Apparent Terminal Half-Life (t1/2) of Pimasertib: Multiple Dose
The apparent terminal half-life was defined as the time required for the plasma concentration of drug to decrease 50% in the final stage of its elimination.
Time frame: Pre dose 0.5, 1.0, 1.5, 2.0, 2.5, 4.0, 6.0, and 10.0 hours post dose in Cycle 1 on Day 19 to Day 21 (Regimen 1 and 2) or Day 26 (Regimen 3).
Part 1: Area Under Curve From Time Zero to Last Sampling Time at Which the Concentration is at or Above Lower Limit of Quantification (AUC0-t) of Pimasertib: Single Dose
Time frame: Predose 0.5, 1.0, 1.5, 2.0, 2.5, 4.0, 6.0, and 10.0 hours post-dose on Day 1 of cycle 1; Regimen 1, 2 and 3
Part 1: Area Under Curve From Time Zero to Last Sampling Time at Which the Concentration is at or Above Lower Limit of Quantification (AUC0-t) of Pimasertib: Multiple Dose
Time frame: Pre dose 0.5, 1.0, 1.5, 2.0, 2.5, 4.0, 6.0, and 10.0 hours post dose in Cycle 1 on Day 19 to Day 21 (Regimen 1 and 2) or Day 26 (Regimen 3).
Part 1: Area Under Plasma Concentration-time Curve From Time Zero Extrapolated to Infinity (AUC0-inf) of Pimasertib: Single Dose
The AUC0-inf was estimated by determining the total area under the curve of the concentration versus time curve extrapolated to infinity. It is obtained from AUC0-t plus AUCt-infinity.
Time frame: Predose 0.5, 1.0, 1.5, 2.0, 2.5, 4.0, 6.0, and 10.0 hours post-dose on Day 1 of cycle 1; Regimen 1, 2 and 3
Part 1: Area Under Plasma Concentration-time Curve From Time Zero Extrapolated to Infinity (AUC0-inf) of Pimasertib: Multiple Dose
The AUC0-inf was estimated by determining the total area under the curve of the concentration versus time curve extrapolated to infinity. It is obtained from AUC0-t plus AUCt-infinity.
Time frame: Pre dose 0.5, 1.0, 1.5, 2.0, 2.5, 4.0, 6.0, and 10.0 hours post dose in Cycle 1 on Day 19 to Day 21 (Regimen 1 and 2) or Day 26 (Regimen 3)
Part 1: Apparent Oral Clearance (CL/f) of Pimasertib: Single Dose
Clearance of a drug was a measure of the rate at which a drug is metabolized or eliminated by normal biological processes. Apparent clearance after oral dose (CL/f) is influenced by the fraction absorbed. Data for Pimasertib 75 mg arm was not available for all the regimens combined, thus reported as separate outcome measure and not included in this outcome.
Time frame: Predose 0.5, 1.0, 1.5, 2.0, 2.5, 4.0, 6.0, and 10.0 hours post-dose on Day 1 of cycle 1; Regimen 1, 2 and 3
Part 1: Apparent Oral Clearance (CL/f) of Pimasertib for Pimasertib 75 mg Reporting Arm: Single Dose
Clearance of a drug was a measure of the rate at which a drug is metabolized or eliminated by normal biological processes. Apparent clearance after oral dose (CL/f) is influenced by the fraction absorbed.
Time frame: Predose 0.5, 1.0, 1.5, 2.0, 2.5, 4.0, 6.0, and 10.0 hours post-dose on Day 1 of cycle 1; Regimen 1, 2 and 3
Part 1: Apparent Oral Clearance (CL/f) of Pimasertib: Multiple Dose
Clearance of a drug was a measure of the rate at which a drug is metabolized or eliminated by normal biological processes. Apparent clearance after oral dose (CL/f) is influenced by the fraction absorbed.
Time frame: Pre dose 0.5, 1.0, 1.5, 2.0, 2.5, 4.0, 6.0, and 10.0 hours post dose in Cycle 1 on Day 19 to Day 21 (Regimen 1 and 2) or Day 26 (Regimen 3)
Part 1: Apparent Oral Volume of Distribution (Vz/f) of Pimasertib:Single Dose
Volume of distribution was defined as the theoretical volume in which the total amount of drug would need to be uniformly distributed to produce the desired serum concentration of a drug. Apparent volume of distribution after oral dose (Vz/f) was influenced by the fraction absorbed. Data for Pimasertib 75 mg arm was not available for all the regimens combined, thus reported as separate outcome measure and not included in this outcome.
Time frame: Predose 0.5, 1.0, 1.5, 2.0, 2.5, 4.0, 6.0, and 10.0 hours post-dose on Day 1 of cycle 1; Regimen 1, 2 and 3
Part 1: Apparent Oral Volume of Distribution (Vz/f) of Pimasertib for Pimasertib 75 mg Reporting Arm:Single Dose
Volume of distribution was defined as the theoretical volume in which the total amount of drug would need to be uniformly distributed to produce the desired serum concentration of a drug. Apparent volume of distribution after oral dose (Vz/f) was influenced by the fraction absorbed.
Time frame: Predose 0.5, 1.0, 1.5, 2.0, 2.5, 4.0, 6.0, and 10.0 hours post-dose on Day 1 of cycle 1; Regimen 1, 2 and 3
Part 1: Apparent Oral Volume of Distribution (Vz/f) of Pimasertib: Multiple Dose
Volume of distribution was defined as the theoretical volume in which the total amount of drug would need to be uniformly distributed to produce the desired serum concentration of a drug. Apparent volume of distribution after oral dose (Vz/f) was influenced by the fraction absorbed.
Time frame: Pre dose 0.5, 1.0, 1.5, 2.0, 2.5, 4.0, 6.0, and 10.0 hours post dose in Cycle 1 on Day 19 to Day 21 (Regimen 1 and 2) or Day 26 (Regimen 3)
Part 1: Percentage of Subjects With Best Overall Response
The best overall response was reported as either of the following: (1) Morphologic complete remission (CR) = normalization of the peripheral blood absolute neutrophil count (PBANC) \>1.0x10\^9 per liter (/L), platelets \>100x10\^9 /L, bone marrow aspirate with less than or equal to (\<=) 5 percent (%) blasts, no blasts with Auer rods (AML only). (2) Complete remission with incomplete blood count recovery (CRi) = Same as CR without normalization of PBANC and platelet count. (3) Partial remission (PR) = normalization of PBANC \>1.0x10\^9/L, platelets \>100x10\^9/L, and at least a 50% decrease in the percentage of marrow aspirate blasts to 5-25%, or marrow blasts less than (\<) 5%. (4) Progressive disease (PD) = \>50% increase in peripheral blood or bone marrow blasts. (5) Stable disease (SD) = Subjects who failed to achieve CR, CRi or PR and without criteria for PD.
Time frame: Day 29 of every alternate 29-day cycle until progression reported between day of first subject randomized, September 2009, until cut-off date, December 2012
Part 2: Number of Subjects With TEAEs, Serious TEAEs, TEAEs Leading to Death and TEAEs Leading to Permanent Treatment Discontinuation
An adverse event (AE) was defined as any new untoward medical occurrences/worsening of pre-existing medical condition, whether or not related to study drug. A serious adverse event (SAE) was an AE that results in any of the following outcomes: death; life threatening; persistent/significant disability/incapacity; initial or prolonged inpatient hospitalization; congenital anomaly/birth defect.
Time frame: Up to 3 years
First/last subject (informed consent): September 2009/12 April 2012. Last subject completed : December 2012; Clinical data cut-off: December 2012.
| Milestone | Regimen 1 (Part 1) | Regimen 2 (Part 1) | Regimen 3 (Part 1) |
|---|---|---|---|
| Started | 33 | 33 | 15 |
| Treated | 33 | 32 | 15 |
| Completed | 33 | 31 | 15 |
| Not completed | 0 | 2 | 0 |
| Withdrew: Ongoing at data cut-off | 0 | 1 | 0 |
| Withdrew: Enrolled but not treated | 0 | 1 | 0 |
The DLT was any toxicity that resulted in treatment delay for more than (\>) 2 weeks due to treatment-related adverse effects, or any Grade greater than or equal to (\>=) 3 non-hematological toxicity excluding Grade 4 asymptomatic increases in liver function tests reversible within 7 days in subjects with liver involvement, and Grade 3 asymptomatic increases in liver function tests reversible within 7 days for subjects without liver involvement, Grade 3 vomiting unless encountered and persistent for more than 3 days despite adequate and optimal therapy, and Grade 3 diarrhea unless encountered and persistent for more than 3 days despite adequate and optimal anti-diarrhea therapy at any DL and judged to be possibly or probably related to the trial treatment by the Investigator and/or the Sponsor.
| subjects | Regimen 1 (Part 1) | Regimen 2 (Part 1) | Regimen 3 (Part 1) |
|---|---|---|---|
| Part 1: Number of Subjects With Dose Limiting Toxicities (DLTs) | 1 | 0 | 5 |
The best overall response was to be reported as either of the following: (1) Morphologic complete remission (CR) = normalization of the peripheral blood absolute neutrophil count (PBANC) \>1.0x10\^9 per liter (/L), platelets \>100x10\^9 /L, bone marrow aspirate with less than or equal to (\<=) 5 percent (%) blasts, no blasts with Auer rods (AML only). (2) Complete remission with incomplete blood count recovery (CRi) = Same as CR without normalization of PBANC and platelet count. (3) Partial remission (PR) = normalization of PBANC \>1.0x10\^9/L, platelets \>100x10\^9/L, and at least a 50% decrease in the percentage of marrow aspirate blasts to 5-25%, or marrow blasts less than (\<) 5%. (4) Progressive disease (PD) = \>50% increase in peripheral blood or bone marrow blasts. (5) Stable disease (SD) = subjects who failed to achieve CR, CRi or PR and without criteria for PD.
No measurements were reported for this outcome.
An adverse event (AE) was defined as any new untoward medical occurrences/worsening of pre-existing medical condition, whether or not related to study drug. A serious adverse event (SAE) was an AE that resulted in any of the following outcomes: death; life threatening; persistent/significant disability/incapacity; initial or prolonged inpatient hospitalization; congenital anomaly/birth defect. TEAEs include both SAEs and non-SAEs.
| Subjects | Regimen 1 (Part 1) | Regimen 2 (Part 1) | Regimen 3 (Part 1) |
|---|---|---|---|
| TEAEs | 33 | 32 | 15 |
| Serious TEAEs | 24 | 28 | 12 |
| TEAEs Leading to Death | 6 | 6 | 5 |
| TEAEs Leading to Treatment Discontinuation | 7 | 7 | 7 |
| nanogram/milliliter | Pimasertib 8 mg (All Regimens [Part 1]) | Pimasertib 15 mg (All Regimens [Part 1]) | Pimasertib 23 mg (All Regimens [Part 1]) | Pimasertib 30 mg (All Regimens [Part 1]) | Pimasertib 42 mg (All Regimens [Part 1]) | Pimasertib 45 mg (All Regimens [Part 1]) | Pimasertib 60 mg (All Regimens [Part 1]) | Pimasertib 75 mg (All Regimens [Part 1]) | Pimasertib 90 mg (All Regimens [Part 1]) |
|---|---|---|---|---|---|---|---|---|---|
| Part 1: Maximum Plasma Concentration (Cmax) of Pimasertib Single Dose | 14.8 ± 43.0 | 29.3 ± 32.0 | 59.1 ± 86.2 | 132.8 ± 29.6 | 151.6 ± 38.8 | 207.0 ± 27.8 | 269.9 ± 46.1 | 241.9 ± 81.0 | 342.6 ± 18.5 |
| nanogram/milliliter | Pimasertib 8 mg (All Regimens [Part 1]) | Pimasertib 15 mg (All Regimens [Part 1]) | Pimasertib 23 mg (All Regimens [Part 1]) | Pimasertib 30 mg (All Regimens [Part 1]) | Pimasertib 42 mg (All Regimens [Part 1]) | Pimasertib 45 mg (All Regimens [Part 1]) | Pimasertib 60 mg (All Regimens [Part 1]) | Pimasertib 75 mg (All Regimens [Part 1]) | Pimasertib 90 mg (All Regimens [Part 1]) |
|---|---|---|---|---|---|---|---|---|---|
| Part 1: Maximum Plasma Concentration (Cmax) of Pimasertib Multiple Dose | 23.6 ± 40.1 | 59.3 ± 53.1 | 69.6 ± 39.2 | 150.1 ± 63.7 | 187.8 ± 25.3 | 123.2 ± 63.4 | 231.4 ± 48.2 | 383.2 ± 57.6 | 486.3 ± NA |
| hour | Pimasertib 8 mg (All Regimens [Part 1]) | Pimasertib 15 mg (All Regimens [Part 1]) | Pimasertib 23 mg (All Regimens [Part 1]) | Pimasertib 30 mg (All Regimens [Part 1]) | Pimasertib 42 mg (All Regimens [Part 1]) | Pimasertib 45 mg (All Regimens [Part 1]) | Pimasertib 60 mg (All Regimens [Part 1]) | Pimasertib 75 mg (All Regimens [Part 1]) | Pimasertib 90 mg (All Regimens [Part 1]) |
|---|---|---|---|---|---|---|---|---|---|
| Part 1: Time to Reach Maximum Plasma Concentration (Tmax): Single Dose | 0.94 ± 41.18 | 2.25 ± 53.20 | 1.56 ± 151.73 | 1.09 ± 38.74 | 1.11 ± 78.05 | 1.12 ± 19.62 | 1.03 ± 40.27 | 2.70 ± 96.84 | 1.17 ± 76.62 |
| hour | Pimasertib 8 mg (All Regimens [Part 1]) | Pimasertib 15 mg (All Regimens [Part 1]) | Pimasertib 23 mg (All Regimens [Part 1]) | Pimasertib 30 mg (All Regimens [Part 1]) | Pimasertib 42 mg (All Regimens [Part 1]) | Pimasertib 45 mg (All Regimens [Part 1]) | Pimasertib 60 mg (All Regimens [Part 1]) | Pimasertib 75 mg (All Regimens [Part 1]) | Pimasertib 90 mg (All Regimens [Part 1]) |
|---|---|---|---|---|---|---|---|---|---|
| Part 1: Time to Reach Maximum Plasma Concentration (Tmax): Multiple Dose | 1.44 ± 78.61 | 1.75 ± 83.12 | 2.03 ± 59.04 | 1.99 ± 70.40 | 1.64 ± 73.93 | 1.41 ± 52.11 | 1.78 ± 112.59 | 2.75 ± 21.83 | 2.00 ± NA |
The apparent terminal half-life was defined as the time required for the plasma concentration of drug to decrease 50% in the final stage of its elimination.
| hour | Pimasertib 8 mg (All Regimens [Part 1]) | Pimasertib 15 mg (All Regimens [Part 1]) | Pimasertib 23 mg (All Regimens [Part 1]) | Pimasertib 30 mg (All Regimens [Part 1]) | Pimasertib 42 mg (All Regimens [Part 1]) | Pimasertib 45 mg (All Regimens [Part 1]) | Pimasertib 60 mg (All Regimens [Part 1]) | Pimasertib 75 mg (All Regimens [Part 1]) | Pimasertib 90 mg (All Regimens [Part 1]) |
|---|---|---|---|---|---|---|---|---|---|
| Part 1: Apparent Terminal Half-Life (t1/2) of Pimasertib: Single Dose | 5.28 ± 41.55 | 3.52 ± 19.75 | 3.05 ± 13.96 | 4.01 ± 36.61 | 3.88 ± 42.26 | 3.45 ± 23.80 | 2.97 ± 21.92 | 4.21 ± 92.04 | 3.39 ± 49.59 |
The apparent terminal half-life was defined as the time required for the plasma concentration of drug to decrease 50% in the final stage of its elimination.
| hour | Pimasertib 8 mg (All Regimens [Part 1]) | Pimasertib 15 mg (All Regimens [Part 1]) | Pimasertib 23 mg (All Regimens [Part 1]) | Pimasertib 30 mg (All Regimens [Part 1]) | Pimasertib 42 mg (All Regimens [Part 1]) | Pimasertib 45 mg (All Regimens [Part 1]) | Pimasertib 60 mg (All Regimens [Part 1]) | Pimasertib 75 mg (All Regimens [Part 1]) | Pimasertib 90 mg (All Regimens [Part 1]) |
|---|---|---|---|---|---|---|---|---|---|
| Part 1: Apparent Terminal Half-Life (t1/2) of Pimasertib: Multiple Dose | 6.97 ± 75.47 | 10.91 ± 590.54 | 3.69 ± 22.69 | 3.93 ± 32.17 | 3.71 ± 21.38 | 3.96 ± 17.24 | 4.52 ± 66.99 | 8.44 ± 175.10 | 5.04 ± NA |
| hour*nanogram/milliliter | Pimasertib 8 mg (All Regimens [Part 1]) | Pimasertib 15 mg (All Regimens [Part 1]) | Pimasertib 23 mg (All Regimens [Part 1]) | Pimasertib 30 mg (All Regimens [Part 1]) | Pimasertib 42 mg (All Regimens [Part 1]) | Pimasertib 45 mg (All Regimens [Part 1]) | Pimasertib 60 mg (All Regimens [Part 1]) | Pimasertib 75 mg (All Regimens [Part 1]) | Pimasertib 90 mg (All Regimens [Part 1]) |
|---|---|---|---|---|---|---|---|---|---|
| Part 1: Area Under Curve From Time Zero to Last Sampling Time at Which the Concentration is at or Above Lower Limit of Quantification (AUC0-t) of Pimasertib: Single Dose | 54.0 ± 57.2 | 125.4 ± 42.4 | 230.9 ± 60.9 | 456.2 ± 25.5 | 581.8 ± 45.4 | 735.2 ± 47.2 | 863.8 ± 52.8 | 905.0 ± 92.8 | 1268.2 ± 31.9 |
| hour*nanogram/milliliter | Pimasertib 8 mg (All Regimens [Part 1]) | Pimasertib 15 mg (All Regimens [Part 1]) | Pimasertib 23 mg (All Regimens [Part 1]) | Pimasertib 30 mg (All Regimens [Part 1]) | Pimasertib 42 mg (All Regimens [Part 1]) | Pimasertib 45 mg (All Regimens [Part 1]) | Pimasertib 60 mg (All Regimens [Part 1]) | Pimasertib 75 mg (All Regimens [Part 1]) | Pimasertib 90 mg (All Regimens [Part 1]) |
|---|---|---|---|---|---|---|---|---|---|
| Part 1: Area Under Curve From Time Zero to Last Sampling Time at Which the Concentration is at or Above Lower Limit of Quantification (AUC0-t) of Pimasertib: Multiple Dose | 131.4 ± 45.5 | 307.2 ± 75.4 | 321.9 ± 29.9 | 679.4 ± 53.7 | 761.2 ± 35.5 | 628.0 ± 28.2 | 991.6 ± 66.1 | 2195.2 ± 97.3 | 2144.7 ± NA |
The AUC0-inf was estimated by determining the total area under the curve of the concentration versus time curve extrapolated to infinity. It is obtained from AUC0-t plus AUCt-infinity.
| hour*nanogram/milliliter | Pimasertib 8 mg (All Regimens [Part 1]) | Pimasertib 15 mg (All Regimens [Part 1]) | Pimasertib 23 mg (All Regimens [Part 1]) | Pimasertib 30 mg (All Regimens [Part 1]) | Pimasertib 42 mg (All Regimens [Part 1]) | Pimasertib 45 mg (All Regimens [Part 1]) | Pimasertib 60 mg (All Regimens [Part 1]) | Pimasertib 75 mg (All Regimens [Part 1]) | Pimasertib 90 mg (All Regimens [Part 1]) |
|---|---|---|---|---|---|---|---|---|---|
| Part 1: Area Under Plasma Concentration-time Curve From Time Zero Extrapolated to Infinity (AUC0-inf) of Pimasertib: Single Dose | 80.5 ± 52.9 | 145.2 ± 42.1 | 315.6 ± 76.3 | 562.1 ± 33.3 | 734.9 ± 49.7 | 858.4 ± 49.6 | 1027.4 ± 49.2 | 1530.7 ± 135.3 | 1873.9 ± 68.8 |
The AUC0-inf was estimated by determining the total area under the curve of the concentration versus time curve extrapolated to infinity. It is obtained from AUC0-t plus AUCt-infinity.
| hour*nanogram/milliliter | Pimasertib 8 mg (All Regimens [Part 1]) | Pimasertib 15 mg (All Regimens [Part 1]) | Pimasertib 23 mg (All Regimens [Part 1]) | Pimasertib 30 mg (All Regimens [Part 1]) | Pimasertib 42 mg (All Regimens [Part 1]) | Pimasertib 45 mg (All Regimens [Part 1]) | Pimasertib 60 mg (All Regimens [Part 1]) | Pimasertib 75 mg (All Regimens [Part 1]) | Pimasertib 90 mg (All Regimens [Part 1]) |
|---|---|---|---|---|---|---|---|---|---|
| Part 1: Area Under Plasma Concentration-time Curve From Time Zero Extrapolated to Infinity (AUC0-inf) of Pimasertib: Multiple Dose | 226.2 ± 91.0 | 789.3 ± 1038.0 | 451.2 ± 39.4 | 1030.2 ± 51.6 | 938.0 ± 46.6 | 786.7 ± 21.2 | 1270.8 ± 104.3 | 2712.6 ± 456.7 | 2830.7 ± NA |
Clearance of a drug was a measure of the rate at which a drug is metabolized or eliminated by normal biological processes. Apparent clearance after oral dose (CL/f) is influenced by the fraction absorbed. Data for Pimasertib 75 mg arm was not available for all the regimens combined, thus reported as separate outcome measure and not included in this outcome.
| liter/hour | Pimasertib 8 mg (All Regimens [Part 1]) | Pimasertib 15 mg (All Regimens [Part 1]) | Pimasertib 23 mg (All Regimens [Part 1]) | Pimasertib 30 mg (All Regimens [Part 1]) | Pimasertib 42 mg (All Regimens [Part 1]) | Pimasertib 45 mg (All Regimens [Part 1]) | Pimasertib 60 mg (All Regimens [Part 1]) | Pimasertib 90 mg (All Regimens [Part 1]) |
|---|---|---|---|---|---|---|---|---|
| Part 1: Apparent Oral Clearance (CL/f) of Pimasertib: Single Dose | 99.43 ± 52.86 | 103.29 ± 42.07 | 72.88 ± 76.28 | 53.37 ± 33.26 | 57.15 ± 49.72 | 52.42 ± 49.59 | 58.40 ± 49.21 | 48.03 ± 68.78 |
Clearance of a drug was a measure of the rate at which a drug is metabolized or eliminated by normal biological processes. Apparent clearance after oral dose (CL/f) is influenced by the fraction absorbed.
| liter/hour | Pimasertib 75 mg (All Regimens [Part 1]) |
|---|---|
| Regimen 1 (n=0) | NA ± NA |
| Regimen 2 (n=3) | 93 ± 103.367 |
| Regimen 3 (n=1) | 45 ± NA |
Clearance of a drug was a measure of the rate at which a drug is metabolized or eliminated by normal biological processes. Apparent clearance after oral dose (CL/f) is influenced by the fraction absorbed.
| liter/hour | Pimasertib 8 mg (All Regimens [Part 1]) | Pimasertib 15 mg (All Regimens [Part 1]) | Pimasertib 23 mg (All Regimens [Part 1]) | Pimasertib 30 mg (All Regimens [Part 1]) | Pimasertib 42 mg (All Regimens [Part 1]) | Pimasertib 45 mg (All Regimens [Part 1]) | Pimasertib 60 mg (All Regimens [Part 1]) | Pimasertib 75 mg (All Regimens [Part 1]) | Pimasertib 90 mg (All Regimens [Part 1]) |
|---|---|---|---|---|---|---|---|---|---|
| Part 1: Apparent Oral Clearance (CL/f) of Pimasertib: Multiple Dose | 60.90 ± 45.51 | 46.74 ± 78.85 | 66.52 ± 33.40 | 37.95 ± 47.59 | 55.80 ± 35.90 | 69.23 ± 33.40 | 65.11 ± 65.69 | 34.44 ± 119.51 | 41.96 ± NA |
Volume of distribution was defined as the theoretical volume in which the total amount of drug would need to be uniformly distributed to produce the desired serum concentration of a drug. Apparent volume of distribution after oral dose (Vz/f) was influenced by the fraction absorbed. Data for Pimasertib 75 mg arm was not available for all the regimens combined, thus reported as separate outcome measure and not included in this outcome.
| liter | Pimasertib 8 mg (All Regimens [Part 1]) | Pimasertib 15 mg (All Regimens [Part 1]) | Pimasertib 23 mg (All Regimens [Part 1]) | Pimasertib 30 mg (All Regimens [Part 1]) | Pimasertib 42 mg (All Regimens [Part 1]) | Pimasertib 45 mg (All Regimens [Part 1]) | Pimasertib 60 mg (All Regimens [Part 1]) | Pimasertib 90 mg (All Regimens [Part 1]) |
|---|---|---|---|---|---|---|---|---|
| Part 1: Apparent Oral Volume of Distribution (Vz/f) of Pimasertib:Single Dose | 757.5 ± 48.3 | 524.8 ± 51.5 | 320.8 ± 60.1 | 308.8 ± 27.1 | 320.2 ± 40.4 | 260.8 ± 46.9 | 250.3 ± 48.5 | 235.2 ± 24.2 |
Volume of distribution was defined as the theoretical volume in which the total amount of drug would need to be uniformly distributed to produce the desired serum concentration of a drug. Apparent volume of distribution after oral dose (Vz/f) was influenced by the fraction absorbed.
| liter | Pimasertib 75 mg (All Regimens [Part 1]) |
|---|---|
| Regimen 1 (n = 0) | NA ± NA |
| Regimen 2 (n = 3) | 442.2 ± 214.6 |
| Regimen 3 (n = 1) | 196.0 ± NA |
Volume of distribution was defined as the theoretical volume in which the total amount of drug would need to be uniformly distributed to produce the desired serum concentration of a drug. Apparent volume of distribution after oral dose (Vz/f) was influenced by the fraction absorbed.
| liter | Pimasertib 8 mg (All Regimens [Part 1]) | Pimasertib 15 mg (All Regimens [Part 1]) | Pimasertib 23 mg (All Regimens [Part 1]) | Pimasertib 30 mg (All Regimens [Part 1]) | Pimasertib 42 mg (All Regimens [Part 1]) | Pimasertib 45 mg (All Regimens [Part 1]) | Pimasertib 60 mg (All Regimens [Part 1]) | Pimasertib 75 mg (All Regimens [Part 1]) | Pimasertib 90 mg (All Regimens [Part 1]) |
|---|---|---|---|---|---|---|---|---|---|
| Part 1: Apparent Oral Volume of Distribution (Vz/f) of Pimasertib: Multiple Dose | 601.7 ± 79.2 | 863.7 ± 193.5 | 332.8 ± 14.5 | 207.8 ± 46.8 | 293.1 ± 27.6 | 395.1 ± 52.9 | 422.0 ± 79.2 | 689.9 ± 16.0 | 305.2 ± NA |
The best overall response was reported as either of the following: (1) Morphologic complete remission (CR) = normalization of the peripheral blood absolute neutrophil count (PBANC) \>1.0x10\^9 per liter (/L), platelets \>100x10\^9 /L, bone marrow aspirate with less than or equal to (\<=) 5 percent (%) blasts, no blasts with Auer rods (AML only). (2) Complete remission with incomplete blood count recovery (CRi) = Same as CR without normalization of PBANC and platelet count. (3) Partial remission (PR) = normalization of PBANC \>1.0x10\^9/L, platelets \>100x10\^9/L, and at least a 50% decrease in the percentage of marrow aspirate blasts to 5-25%, or marrow blasts less than (\<) 5%. (4) Progressive disease (PD) = \>50% increase in peripheral blood or bone marrow blasts. (5) Stable disease (SD) = Subjects who failed to achieve CR, CRi or PR and without criteria for PD.
| Percentage of Subjects | Regimen 1 (Part 1) | Regimen 2 (Part 1) | Regimen 3 (Part 1) |
|---|---|---|---|
| CR | 0.0 | 0.0 | 0.0 |
| CRi | 0.0 | 0.0 | 0.0 |
| PR | 0.0 | 0.0 | 0.0 |
| SD | 60.0 | 77.3 | 71.4 |
| PD | 40.0 | 22.7 | 28.6 |
An adverse event (AE) was defined as any new untoward medical occurrences/worsening of pre-existing medical condition, whether or not related to study drug. A serious adverse event (SAE) was an AE that results in any of the following outcomes: death; life threatening; persistent/significant disability/incapacity; initial or prolonged inpatient hospitalization; congenital anomaly/birth defect.
No measurements were reported for this outcome.
Collected over Up to 3 years. Non-serious events are listed at a 0% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Regimen 1 (Part 1) | — | 24/33 (72.7%) | 32/33 (97%) |
| Regimen 2 (Part 1) | — | 28/32 (87.5%) | 30/32 (93.8%) |
| Regimen 3 (Part 1) | — | 12/15 (80%) | 15/15 (100%) |
| Event | Regimen 1 (Part 1) | Regimen 2 (Part 1) | Regimen 3 (Part 1) |
|---|---|---|---|
| Febrile NeutropeniaBlood and lymphatic system disorders | 4/33 | 9/32 | 2/15 |
| PneumoniaInfections and infestations | 7/33 | 4/32 | 3/15 |
| PyrexiaGeneral disorders | 1/33 | 5/32 | 1/15 |
| DiarrhoeaGastrointestinal disorders | 2/33 | 2/32 | 2/15 |
| Pleural EffusionRespiratory, thoracic and mediastinal disorders | 1/33 | 0/32 | 2/15 |
| CellulitisInfections and infestations | 2/33 | 3/32 | 0/15 |
| SepsisInfections and infestations | 2/33 | 3/32 | 1/15 |
| EpistaxisRespiratory, thoracic and mediastinal disorders | 3/33 | 0/32 | 1/15 |
| ThrombocytosisBlood and lymphatic system disorders | 0/33 | 0/32 | 1/15 |
| Cardiac failure congestiveCardiac disorders | 1/33 | 0/32 | 1/15 |
| Event | Regimen 1 (Part 1) | Regimen 2 (Part 1) | Regimen 3 (Part 1) |
|---|---|---|---|
| DiarrhoeaGastrointestinal disorders | 14/33 | 16/32 | 8/15 |
| NauseaGastrointestinal disorders | 10/33 | 7/32 | 2/15 |
| Oedema peripheralGeneral disorders | 6/33 | 8/32 | 4/15 |
| HypocalcaemiaMetabolism and nutrition disorders | 1/33 | 2/32 | 4/15 |
| RashSkin and subcutaneous tissue disorders | 4/33 | 6/32 | 4/15 |
| PyrexiaGeneral disorders | 7/33 | 8/32 | 1/15 |
| Aspartate aminotransferase increasedInvestigations | 8/33 | 7/32 | 3/15 |
| DizzinessNervous system disorders | 7/33 | 5/32 | 2/15 |
| HyperuricaemiaMetabolism and nutrition disorders | 2/33 | 3/32 | 3/15 |
| HypoalbuminaemiaMetabolism and nutrition disorders | 1/33 | 2/32 | 3/15 |
Baseline analysis population included all the subjects who were treated with at least one administration of pimasertib.
| Age, Customized(Subjects) | Regimen 1 (Part 1) | Regimen 2 (Part 1) | Regimen 3 (Part 1) | Total |
|---|---|---|---|---|
| 18 to less than (<) 60 | 14 | 12 | 6 | 32 |
| 60 to <75 | 13 | 16 | 6 | 35 |
| Greater than or equal to (>=) 75 | 6 | 4 | 3 | 13 |
| Sex: Female, Male(Participants) | Regimen 1 (Part 1) | Regimen 2 (Part 1) | Regimen 3 (Part 1) | Total |
|---|---|---|---|---|
| Female | 9 | 13 | 7 | 29 |
| Male | 24 | 19 | 8 | 51 |
Ran from Sep 2009 to primary completion in Dec 2012, 39 months.
Results were first posted in Mar 2017, 4 years 2 months after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is terminated, as verified in Jul 2017. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Pimasertib